Introduction:
Desmopressin is commonly used to reduce bleeding in patients with mucocutaneous bleeding disorders and is available in both intravenous and intranasal forms. Given the variability in response to desmopressin at an individual level, its effectiveness should be assessed with a test dose prior to being advised for use. At this time, no trial has extensively compared the use of intranasal desmopressin to intravenous desmopressin.
Aims:
To determine whether both forms of desmopressin are equally effective in yielding a positive response in laboratory assays in paediatric patients with von
Willebrand disease or probable von Willebrand disease.
Methods:
We evaluated medical record data for 58 patients who underwent desmopressin stimulation testing in our haematology clinic during a 1-year period. Data were collected on demographic information and haematologic laboratory assays prior to desmopressin administration and one hour following desmopressin.
Results:
There was an absolute increase in von Willebrand antigen to levels appropriate for haemostasis following both forms of desmopressin, although this increase was significantly greater in the intravenous group compared to the intranasal group.
There was also a significant absolute increase in Ristocetin Cofactor and Factor VIII levels following desmopressin in both groups.
Conclusion:
Both intravenous and intranasal forms of desmopressin produce a positive response during desmopressin stimulation testing and can be used to identify patients for whom this medication would be effective.
K E Y W O R D S
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There is no current guideline which directs practitioners as to which form of desmopressin is optimal for use in desmopressin stimulation testing. Currently, at our institution, the preparation used for stimulation testing is based upon the geographic location of the Hematology Clinic appointment. Studies comparing the haemostatic effects of intranasal and intravenous desmopressin in the paediatric population are limited. Our primary goal of this study was to ascertain whether intravenous and intranasal desmopressin yield the same rates of positive response of laboratory assays in VWD. Our secondary goal was to identify whether any other clinical predictors of response could be identified. Demographic data between the intranasal and intravenous desmopressin groups were compared using t test of means for continuous variables and χ 2 test or Fisher's exact test for binomial data. A 2-tailed independent t test of means was used to compare the absolute increase in laboratory assays above baseline (pretest value subtracted from post-test value) and the relative increase in assays above baseline (n-fold above baseline, or posttest value divided by pretest value). Mixed-effects models were used to assess whether desmopressin form resulted in differing degrees of response, with random effects parameters to adjust for baseline patient levels. In these models, we further adjusted for potential confounding by age, weight and oral contraceptive use based on prior knowledge. This project was reviewed by the University of Pittsburgh Institutional Review Board and qualified for exemption.
| MATERIAL S AND ME THODS

| RE SULTS
Using our electronic medical record, we initially identified 99 patient encounters. Of these, 58 patient encounters were eligible for inclusion. Reasons for exclusion included duplicate orders, patients who did not present for testing after desmopressin was ordered, patients for whom laboratory data for pre-and post-testing of at least one laboratory assay was not obtained and patients with platelet function defects. Among the 58 patient encounters reviewed, 32 patients underwent testing with intranasal desmopressin and 26 patients underwent testing with intravenous desmopressin. A majority of patients were female and of adolescent age. Hormonal contraceptive use was about twice as prevalent in the intranasal group (34% vs 19%). Overall, though, there was no significant difference between groups in terms of sex, weight, hormonal contraceptive use or haematologic diagnosis (Table 1 ). The two groups were significantly different in terms of mean age of patients, with patients in the IV group being younger.
We detected a statistically significant difference in the absolute increase in VWF:Ag levels following treatment, with the intravenous group showing an increase in greater magnitude than the intranasal group (1.26 vs 0.95 U/mL). There were smaller, but not statistically significant differences, in the absolute increase in VWF:RCo levels (1.08 vs 0.96 U/mL) and FVIII:C levels (1.55 vs 1.32 U/mL).
There were no significant differences between the intranasal and intravenous groups in terms of the relative increase above baseline (Table 2) .
Mixed-effects models were used to compare the improvement in assays across desmopressin groups, adjusting for differences in baseline factors such as age and oral contraceptive use. Oral contraceptive use, age and weight were not found to have a significant effect on patient response to desmopressin and do not appear to have a confounding effect on interpreting the difference in test results based on desmopressin form (Table 3) .
| D ISCUSS I ON
In this study, we found that both intravenous and intranasal desmopressin were effective in producing a response in VWF:Ag, VWF:RCo, and FVIII:C levels. The absolute increase between pretest and post-test values of all of these assays was statistically significant, with only the absolute increase in VWF:Ag being significantly different between the intravenous group and the intranasal group.
When evaluating the response to desmopressin, we typically consider a "positive response" as generating a twofold or greater increase in von Willebrand antigen, Ristocetin Cofactor, or Factor VIII level (also described here as the relative increase in levels). Peak levels occur thirty to ninety minutes after a dose. 2 Therefore, we would expect to identify a responder in most cases by levels drawn at sixty minutes. Both the intravenous and the intranasal desmopressin groups had a mean increase above baseline that was greater than twofold for all three laboratory assays, with no significant difference between groups. Although we previously noted the absolute increase in von Willebrand antigen above baseline was of a greater magnitude in the intravenous group, the absolute incremental 
TA B L E 3
Results of mixed-effects model, numerical value represents the average change in laboratory assay associated with hormonal contraceptive use or with one unit increase in age or weight response produced by desmopressin is not often used to determine whether a patient has responded adequately. It is also unclear if this difference is clinically significant, the mean absolute increase in von Willebrand antigen in the intranasal group was 0.96 U/mL.
This would be sufficient to increase von Willebrand antigen to a level appropriate for haemostasis.
Although there was a significant difference between the two groups in terms of mean age of patients, with the IV group consisting of younger patients, the mixed model analysis suggests that age is not strongly associated with test results and therefore does not appear to confound results. Perhaps younger patients were more likely to go undergo testing with IV desmopressin as it was felt they would not tolerate an intranasal form of medication. Mixed model analysis also demonstrates that weight and oral contraceptive use are not strongly associated with test results. While these factors may be important for patient care, they do not seem to necessarily bear any weight in helping clinicians predict which patients will be desmopressin responders. There may be other differentiating factors present which we have not yet identified.
At this time, there is limited information in the literature on the use of intranasal desmopressin in the paediatric population. A large study of both adult and paediatric patients looking at the use of intranasal desmopressin for control of bleeding symptoms found this form of desmopressin to be subjectively effective and was well tolerated in the majority of patients. 6 However, objective data on response of laboratory parameters were only obtained in a small subset of patients and no comparison to intravenous desmopressin was made. Khair et al 7 also demonstrated that intranasal desmopressin appeared to be effective in a small group of paediatric patients with either haemophilia or von Willebrand disease but did not make a direct comparison to intravenous desmopressin. We did find one study which compared response to intranasal desmopressin with historic response to intravenous desmopressin within the same small group of paediatric patients. 8 However, to our knowledge, our study is the largest to specifically compare these two forms of desmopressin in the paediatric population.
There are several limitations to our study. We believe that our study population is representative of the local population of patients with von Willebrand disease, as our hospital is a large referral centre. However, some patients with suspected von Willebrand disease may have been referred to the regional Hemophilia Treatment
Center for evaluation. In addition, the decision of desmopressin form to use for stimulation testing was made based on geographic location rather than in a randomized fashion. We do not believe the above factors substantially effected our results, as the only significant difference in demographic characteristics between groups was in age. Furthermore, all laboratory assays were processed in same lab, which was physically separate from both testing locations. We did have notably fewer male patients in each group, likely attributed to the fact that females are more likely to undergo investigation for a mucocutaneous bleeding disorder in relation to heavy menstrual bleeding. This difference in male subjects was seen equally in both groups. Finally, we noted that both groups had a small set of patients which met laboratory criteria for VWD. For the purposes of this study, we identified patients as having VWD versus probable VWD based upon laboratory values available in our medical record.
However, for some of our patients, the initial diagnostic testing was completed outside of our hospital system and results were unavailable for review. Laboratory values for Ristocetin Cofactor and von
Willebrand antigen are known to fluctuate based upon a variety of factors and it is possible that a larger number of patients met laboratory criteria for VWD.
In summary, this study suggests that both intravenous and intranasal forms of desmopressin may be efficacious for stimulation testing. A shift to using intranasal desmopressin preparations when possible is desirable as it may improve patient experience as well as quality of life, including fewer trips to tertiary care centres and increased personal responsibility for disease management. Directions for future studies would include prospectively evaluating the effect of desmopressin form on effectiveness by utilizing a randomized study design. We would also be interested in learning if both forms of desmopressin are effective in other patient populations for which desmopressin is used, such as patients with haemophilia or certain platelet function defects.
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